Closing in on Myc inhibition: a marathon sprint finish?

by VHIO

3 years ago
Myc inhibitor, inhibitor, Cancer

We have come a long way to get to this point, with many twists and unexpected turns. A voyage which we have been fortunate to navigate alongside many other expert teams, investigators at biotech and p...

A molecular classification predicts the prognosis and the benefit of a cell cycle inhibitor in metastatic breast cancer

by Fundació Clínic per a la Recerca Biomèdica

3 years ago
metastatic breast cancer, molecular classification, inhibitor

In a study published in the Journal of Clinical Oncology, researchers from the Hospital Clínic-IDIBAPS-UB and SOLTI showed the predictive capacity of the 4 molecular subtypes of breast cancer (Lumina...

XOMA and Inveready Acquires Royalty Interest Position in Six Clinical-Stage Assets from Palobiofarma

by Palobiofarma

5 years ago
Novartis, Inveready, tumor, inhibitor, adenosine

XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.One of the asse...

WHO recommends an integrase inhibitor as preferred HIV treatment option in all populations

by Fundació Bancària 'la Caixa'

5 years ago
epidemic, HIV, OMS, inhibitor

The WHO Guideline Development Group decided to recomment dolutegravir as the preferred first-line and second-line treatment for all populations, in contrast with initial studies.